Dtsch Med Wochenschr 2014; 139(22): 1175-1180
DOI: 10.1055/s-0034-1369992
Übersicht | Review article
Immunologie
© Georg Thieme Verlag KG Stuttgart · New York

Die Eosinophilie – Inflammation, Proliferation, Reaktion

Teil 2: Spezielle KrankheitsbilderEosinophilia – inflammation, proliferation, reaction. Part 2: Specific diseases
L. Balke
1   Klinik für Innere Medizin I, Schwerpunkt Pneumologie
,
A. Günther
2   Klinik für Innere Medizin II, Sektion für Stammzell- und Immuntherapie
,
R. Zeuner
3   Klinik für Innere Medizin I, Schwerpunkt Rheumatologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel
,
B. Bewig
1   Klinik für Innere Medizin I, Schwerpunkt Pneumologie
› Author Affiliations
Further Information

Publication History

27 April 2013

09 December 2013

Publication Date:
20 May 2014 (online)

 
  • Literatur

  • 1 Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135: 805-826
  • 2 Bain B, Fletcher S. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007; 27: 377-388
  • 3 Bittmann I, Holl-Ulrich K. Histomorphologie interstitieller Lungengerüstveränderungen und pulmonaler Vaskulitiden. Z Rheumatol 2009; 68: 639-649
  • 4 Campos LE, Pereira LF. Pulmonary eosinophilia. J Bras Pneumol 2009; 25: 561-573
  • 5 Celestin J, Frieri M. Eosinophilic disorders in various diseases. Curr Allerg Asthma Rep 2012; 12: 18-24
  • 6 Chusid MJ, Dale DC, West BC et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27
  • 7 d'Elbée JM, Parrens M, Mercié P et al. Hypereosinophilic syndrome – lymphocytic variant transforming into peripheral T-cell lymphoma with severe oral manifestations. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 116: e185-190
  • 8 Frankel SK, Cosgrove GP, Fischer A et al. Update in the diagnosis and management of pulmonary vasculitis. Chest 2006; 129: 452-465
  • 9 Garret JK, Jameson SC, Thomson B et al. Anti-interleukin-5 (Mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113: 115-119
  • 10 Harfi I, Schandené L, Dremier S et al. Eosinophils affect functions of in vitro-activated human CD3-CD4+ T cells. Journal of Translational Medicine 2013; 11: 112
  • 11 Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J et al. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Hematologica 2009; 94: 1236-1241
  • 12 Hellmich B, Holl-Ulrich K, Gross WL. Hypereosinophiles Syndrom: aktueller Stand der Diagnostik und Therapie. Dtsch Med Wochenschr 2007; 132: 1892-1896
  • 13 Hellmich B, Holl-Ulrich K, Gross WL. Hypereosinophiles Syndrom und Churg-Strauss Syndrom. Internist 2008; 49: 286-296
  • 14 Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing / refractory Churg-Strauss Syndrome. Clin Exp Rheumatol 2012; 30: 62-65
  • 15 Janz DR, O`Neal HR, Ely EW. Acute eosinophilic pneumonia: a case report and review of the literature. Crit Care Med 2009; 37: 1470-1474
  • 16 Kirsten D, Costabel U. Seltene Lungenkrankheiten. Großhansdorf: Inter-Pneu-Verlag; 2002
  • 17 Klion A. Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med 2009; 60: 293-306
  • 18 Klion A. Eosinophilic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2011; 2011: 257-263
  • 19 Klion A, Bochner BS, Gleich GJ et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117: 1292-1302
  • 20 Koczulla AR, Beutel B, Greulich T et al. Allergische Reaktionen der Lunge. Internist 2012; 53: 924-933
  • 21 Lierman E, Selleslag D, Smits S et al. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood 2012; 120: 1529-1531
  • 22 Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets in ANCA-associated Vasculitis. NEJM 2012; 367: 214-223
  • 23 Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002; 107: 101-107
  • 24 Marchand E, Cordier JF. Ideopathic chronic eosinophilic pneumonia. Semin Respir Crit Care Med 2006; 27: 134-141
  • 25 Masi AT, Hunder GG, Lie JT et al. the American College of Rheumatology 1990 Criteria for the classification of Churg-Strauss Syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094-1100
  • 26 Metzgeroth G, Walz C, Score J et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007; 21: 1183-1188
  • 27 Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Immunol Allergy Clin North Am 2007; 27: 529-549
  • 28 Ogbogu PU, Bochner BS, Butterfield JH et al. Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124: 1319-1325
  • 29 Patterson K, Strek ME. Allergic bronchopulmonary aspergillosis. Proc Am Thorac Soc 2010; 7: 237-244
  • 30 Patterson R, Greenberger PA, Harris KE. Allergic bronchopulmonary aspergillosis. Chest 2000; 118: 7-8
  • 31 Philit F, Etienne-Mastroianni B, Parrot A et al. Ideopathic acute eosinophilic pneumonia. Am J Respir Crit Care Med 2002; 166: 1235-1239
  • 32 Poletti V, Costabel U, Casoni GL et al. Rare infiltrative lung diseases: a challenge for clinicans. Respiration 2004; 71: 431-443
  • 33 Reiter A, Goede J, Metzgeroth G, Sperr WR, Valent P. Eosinophilie-assoziierte Myeloproliferative Erkrankungen (MPN-Eo). Leitlinie der DGHO, Stand September 2011
  • 34 Rosenberg M, Patterson R, Mintzer R et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977; 86: 405-414
  • 35 Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107: 113-122
  • 36 Swerdlow SH, Campo E, Harris NL et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008: 51 ff
  • 37 Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 2010; 85: 158-164
  • 38 Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal, idiopathic. British Journal of Haematology 2006; 133: 468-492
  • 39 Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organisation Classification System for meloproliferative neoplasms. Order out of chaos. Cancer 2009; 115: 3842-3847
  • 40 Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organisation Criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22
  • 41 Vardiman J, Hyjek E. World Health Organisation Classification. Evaluation and genetics of the myeloproliferative neoplasm variants. Hematology Am Soc Hematol Educ Program 2011; 2011: 250-256
  • 42 Valtent P, Klion AD, Horny HP et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130: 607-612
  • 43 Young M, Rodak R, Stüssi G et al. Eosinophilie – Differentialdiagnose und Abklärung. Praxis 2009; 98: 797-806
  • 44 Zwerina J. Das Churg-Strauss-Syndrom. Z Rheumatol 2008; 67: 137-144